Ozempic vs Wegovy: Same Drug, Different Purpose

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — made by the same manufacturer (Novo Nordisk). The difference is what they're approved for and how they're dosed. Ozempic is FDA-approved for type 2 diabetes (max dose 2.0 mg). Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg).

Understanding the difference matters for insurance coverage, prescribing, and what you can expect from each.

Side-by-Side Comparison

	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA indication	Type 2 diabetes	Chronic weight management
Year approved	2017	2021
Max dose (injection)	2.0 mg weekly	2.4 mg weekly
Dose options	0.25, 0.5, 1.0, 2.0 mg	0.25, 0.5, 1.0, 1.7, 2.4 mg
Oral formulation	Yes (Rybelsus, for T2D)	Yes (oral Wegovy, approved 2025)
CV outcomes data	Not indicated for CV risk	FDA-approved for CV risk reduction (SELECT)
List price	~$935/month	~$1,349/month
Insurance coverage	Broad (T2D)	Growing (weight management)

Why the Same Drug Has Two Names

Pharmaceutical companies routinely market the same molecule under different brand names for different indications. This is a regulatory and commercial strategy, not a medical one.

Ozempic was developed first (approved 2017) for type 2 diabetes. Novo Nordisk then conducted the STEP clinical trial program to prove semaglutide's effectiveness for weight loss at a higher dose. Wegovy was approved in 2021 specifically for chronic weight management.

Separate brands allow for:

Different FDA approvals — each indication requires separate clinical trials and regulatory review
Different insurance coverage — diabetes coverage is broader than obesity coverage
Different dosing — Wegovy goes to 2.4 mg; Ozempic maxes at 2.0 mg
Targeted marketing — patients and doctors associate each brand with its purpose

Dosing Differences

The most meaningful clinical difference between Ozempic and Wegovy is the maximum dose.

Titration Step	Ozempic	Wegovy
Starting dose	0.25 mg (weeks 1-4)	0.25 mg (weeks 1-4)
Step 2	0.5 mg (weeks 5-8)	0.5 mg (weeks 5-8)
Step 3	1.0 mg (maintenance or continue)	1.0 mg (weeks 9-12)
Step 4	2.0 mg (optional max)	1.7 mg (weeks 13-16)
Step 5	—	2.4 mg (maintenance)

Wegovy's higher maximum dose (2.4 mg vs 2.0 mg) explains why the STEP trials showed more weight loss than what Ozempic typically achieves at its approved doses. The additional 0.4 mg may seem small, but it represents a 20% higher dose at the top end.

Weight Loss at Different Doses

Drug & Dose	Trial	Duration	Weight Loss
Wegovy 2.4 mg	STEP 1	68 weeks	-14.9%
Ozempic 2.0 mg	STEP 5 (extended dose)	68 weeks	~-15%
Ozempic 1.0 mg	SUSTAIN-1	30 weeks	-3.7 kg
Ozempic (off-label, general)	Real-world data	Varies	~5-10%
Oral Wegovy 50 mg	OASIS 1	68 weeks	-15.1%

At comparable doses, Ozempic and Wegovy produce similar weight loss — because they are the same drug. The clinical trial difference comes primarily from dose (Wegovy reaches 2.4 mg) and the trial population (STEP trials enrolled for obesity; SUSTAIN for diabetes).

Insurance and Coverage Differences

This is where the brand distinction matters most practically.

	Ozempic	Wegovy
Covered for diabetes	Yes (broadly)	Sometimes (depends on plan)
Covered for weight loss	No (off-label)	Increasingly (varies by plan)
Medicare coverage	Yes (for diabetes)	Expanding under AOM provisions
Prior authorization	Often required	Usually required
Step therapy	May require trying metformin first	May require documenting failed lifestyle changes

Many patients take Ozempic off-label for weight loss because their insurance covers it for diabetes but not Wegovy for weight loss. This is common but means the patient may not reach the optimal weight loss dose (2.4 mg) since Ozempic's approved max is 2.0 mg.

Oral Wegovy

In 2025, the FDA approved oral semaglutide tablets specifically for weight loss under the Wegovy brand. This is a significant milestone — it is the first oral GLP-1 drug approved for chronic weight management.

Oral Wegovy delivered -15.1% weight loss at 68 weeks in the OASIS 1 trial — comparable to injectable Wegovy. This removes the injection barrier for patients who prefer a daily pill.

Oral semaglutide was previously only available as Rybelsus (lower doses, for type 2 diabetes). Oral Wegovy uses a higher dose (50 mg daily) optimized for weight loss.

Off-Label Use Considerations

Many doctors prescribe Ozempic off-label for weight loss because:

Insurance coverage for diabetes drugs is broader
Ozempic has been available longer with a well-established safety profile
Wegovy has experienced supply shortages

However, off-label use means:

The maximum approved Ozempic dose (2.0 mg) is lower than Wegovy's (2.4 mg)
Insurance may not cover the off-label use if the patient doesn't have diabetes
Clinical trial data specifically supporting weight loss efficacy used the Wegovy dosing

If weight loss is the primary goal, discuss with your doctor whether Wegovy (or its oral formulation) is a better fit than Ozempic.

Beyond Semaglutide: The Next Generation

Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist. Newer drugs target additional receptors for greater efficacy:

Tirzepatide (Mounjaro/Zepbound) — dual GLP-1 + GIP agonist, -22.5% weight loss. See Mounjaro vs Ozempic and Zepbound vs Wegovy.
Retatrutide — triple GLP-1 + GIP + glucagon agonist, -28.7% weight loss. Not yet approved (expected 2027). See Retatrutide vs Wegovy.

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

Yes. Both contain semaglutide, made by Novo Nordisk. The difference is the FDA indication (Ozempic for type 2 diabetes, Wegovy for weight management) and maximum dose (Ozempic 2.0 mg, Wegovy 2.4 mg).

Why is Wegovy more expensive than Ozempic?

Wegovy is priced higher (~$1,349/mo vs ~$935/mo) partly because it is marketed for weight management — a newer and less broadly covered indication. Ozempic benefits from wider insurance formulary placement for diabetes.

Can I use Ozempic instead of Wegovy for weight loss?

Many doctors prescribe Ozempic off-label for weight loss. It contains the same drug but the maximum approved dose is 2.0 mg vs Wegovy's 2.4 mg. If weight loss is your primary goal, discuss with your doctor whether Wegovy is more appropriate.

Does Wegovy come as a pill?

Yes. The FDA approved oral Wegovy (semaglutide tablets, 50 mg daily) for weight management in 2025. It produced similar weight loss to the injectable form (-15.1% at 68 weeks in OASIS 1).

Which has better insurance coverage — Ozempic or Wegovy?

Ozempic generally has broader insurance coverage because diabetes coverage is more established. Wegovy coverage for weight management is growing but still varies significantly by plan. Many plans require prior authorization for both.

What is the difference between Ozempic and Rybelsus?

Both are semaglutide made by Novo Nordisk. Ozempic is a once-weekly injection (up to 2.0 mg) for type 2 diabetes. Rybelsus is a daily oral tablet (3, 7, or 14 mg) for type 2 diabetes. They are the same molecule in different formulations.

Sources

Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
Knop, F.K., et al. (2023). Oral Semaglutide 50 mg Taken Once Daily in Adults with Overweight or Obesity (OASIS 1). The Lancet. DOI: 10.1016/S0140-6736(23)01185-6
Novo Nordisk. (2025). Wegovy Pill Availability Announcement. Press release.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources